About Us
The Health Thread
Ethical Health Journalism
Live
🌍Community Power: DRC's Success in Battling Ebola Outbreaks Through Local Engagement🌍Uganda Begins Crucial Countdown to Declare End of Ebola Outbreak🌍Ebola Outbreak in DR Congo: Building Trust Critical for Healthcare Access in Goma🌍CAR Battles Cholera Outbreak Amidst Displacement and Aid Challenges🌍Syria Strengthens Public Health Defenses with Advanced Disease Detective Training, Integrating AI🌍Community Power: DRC's Success in Battling Ebola Outbreaks Through Local Engagement🌍Uganda Begins Crucial Countdown to Declare End of Ebola Outbreak🌍Ebola Outbreak in DR Congo: Building Trust Critical for Healthcare Access in Goma🌍CAR Battles Cholera Outbreak Amidst Displacement and Aid Challenges🌍Syria Strengthens Public Health Defenses with Advanced Disease Detective Training, Integrating AI
Research Watch
•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•Why Your Lungs May Hold the Secret to Your Stress Levels•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•Why Your Lungs May Hold the Secret to Your Stress Levels

Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals.

Researchers

Nada R Abuknesha, James H O'Keefe, Frank Qian, Nathan L Tintle, Yidie Lin, Yue Sun, Han-Zhu Qian, Paul S Aisen, Christine M Albert, William J Aronson, Abdul Aziz A Asbeutah, Heike A Bischoff-Ferrari, Matthew J Budoff, Nicholas R Burns, Cecilia A Cardenas, Cynthia M Carlsson, Emily Y Chew, Neal J Cohen, Léopold K Fezeu, Amana Liddell, Pilar Galan, Mark A Hull, Tsuo-Hung Lan, Pan-Yen Lin, Alexia Mengelberg, Anne-Marie Minihane, Joseph F Quinn, Thomas A B Sanders, Andrew Scholey, David A Schoenfeld, Kirsty Sprange, Kuan-Pin Su, Christopher H van Dyck, Carol A Van Hulle, David Vauzour, Claire Weber, Francine K Welty, Gary Wittert, William S Harris

Abstract

Recent meta-analyses of randomized controlled trials have raised concerns that treatment with omega-3 fatty acids may increase the risk of atrial fibrillation (AF). However, these meta-analyses included at most 8 trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 randomized controlled trials with AF incidence data, incorporating both published and unpublished data. Eligible studies were randomized controlled trials investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months of treatment with EPA/DHA, participants ≥50 years of age, and, where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was the occurrence of new-onset AF. Our primary hypothesis was that risk for AF would simultaneously depend on both omega-3 dose (above or below 1500 mg/d) and background cardiovascular disease risk status, and that their combined impact on AF risk would be synergistic. A total of 35 randomized controlled trials (37 data sets; n=114 592) were included in this meta-analysis. Only studies including patients at high-risk for cardiovascular disease who were treated with high-doses of EPA/DHA (>1500 mg/d) showed a statistically significant increase in AF risk with a pooled odds ratio (OR) of 1.43 (95% CI, 1.14-1.79) and an absolute risk difference of 0.8% (0.40%-1.1%). None of the other 3 groups showed statistically significant levels of AF risk (odds ratios, 1.07 [high risk-low dose], 1.06 [low risk-low dose], and 1.03 [low risk-high dose]). This meta-analysis suggests that high-dose EPA/DHA treatment is associated with an increased risk of AF in patients at high cardiovascular disease risk, whereas low-dose EPA/DHA does not appear to increase AF risk, even in high-risk populations. Further prospective studies are needed to evaluate any potential increased risk of higher doses balanced against potential benefits.
Source: PubMed (PMID: 42517224)View Original on PubMed